Replens HCP

Provides immediate relief to dry vaginal cells

Trusted by HCPs2, loved by patients3

Order Your FREE Replens MD™ Patient Trial Pack

Vaginal Dryness

Vaginal atrophy is a common but often overlooked concern for peri- and post-menopausal women.4 Perimenopause can last for several years, during which symptoms such as vaginal dryness, irritation, and discomfort can significantly impact a woman’s quality of life.4,5

Prevalence:

of women experience symptoms like vaginal dryness during menopause.5

Persistence:

of postmenopausal women identify vaginal dryness as the most common issue.6 These symptoms can last for months or even years.

Impact:

of postmenopausal women in the UK experience disrupted intimacy with their partner because of vaginal atrophy.7 But the effects go beyond intimacy. Vaginal dryness often impacts confidence, self-esteem, and everyday comfort, making it a challenge that requires more than a temporary solution.5,6

Recommend Replens MD™ Moisturiser alongside HRT

Be an advocate for your HRT patients

While HRT is effective for many menopausal symptoms, it can take up to 3 months to alleviate vaginal dryness, and for some women, symptoms may persist even with treatment.8

By hydrating the vaginal tissues, Replens MD™ Moisturiser bridges the gap during the waiting period, ensuring patients experience comfort and confidence sooner.8-11

Replens MD™ Moisturiser provides immediate relief to dry vaginal cells. Hormone-free and can be used alongside HRT.

Why Choose Replens MD™ Moisturiser

Replens MD™ Moisturiser is a trusted, clinically tested solution that complements HRT by addressing vaginal dryness effectively:9

Provides moisture at the source of discomfort

Provides immediate relief to dry vaginal cells.

Long-term comfort

An effective long-term solution for improving vaginal health and hydration that can be used for many years.

Sustained relief

Contains a bioadhesive polymer, polycarbophil gel, that adheres to the vaginal tissue and releases water slowly to provide soothing, sustained relief.9,10,13

Lubricants alone aren’t always enough

While lubricants may provide temporary relief, they fail to address the underlying causes of vaginal atrophy.12 Replens MD™ Moisturiser maintains vaginal moisture over time, lasting up to 3 days per application.12

Hormone-free & NICE recommended

Suitable for women who cannot or choose not to use hormonal treatments and is recommended by name in the NICE guidelines as a first-line option alongside vaginal oestrogen.1

Suitability

Replens MD™ Moisturiser can be used in patients with breast cancer, diabetes, high blood pressure, liver problems, with a history of blood clots or who experience migraines or severe headaches.8

Clinical Evidence

In a 12-week, open-label study of 30 postmenopausal women, Replens MD™ Moisturiser was shown to increase vaginal moisture by 35% in 4 weeks (p<0.005) and 40% in 12 weeks (p<0.005).10

In a 12-week, open-label study of 30 postmenopausal women, Replens MD™ Moisturiser was shown to increase vaginal elasticity by 26% in 12 weeks (p<0.02).10

In a 12-week, open-label study of 30 postmenopausal women, Replens MD™ Moisturiser was shown to reverse vaginal atrophy in 60% of women in 12 weeks.10

In a randomised open-label study of 39 women, 60% of postmenopausal women using Replens MD™ Moisturiser rated its effects as being excellent to good.14

How Replens MD™ Moisturiser Works

Dry, compacted vaginal cells

A lack of oestrogen causes thinning and shrinking of the vaginal mucosa.11

Moisture locking power

Replens MD™ Moisturiser contains polycarbophil, which can carry up to 60 times its weight in water, providing hydration.9

Up to 72-hour hydration

The polycarbophil bioadhesive system binds to the vaginal lining up to 72 hours, forming a protective film that releases purified water to hydrate underlying tissues.13

Replens MD™ Moisturiser delivers effective hydration through its polycarbophil-based bioadhesive gel, which:
1. Adheres to the vaginal lining to form a protective barrier.9,13
2. Releases purified water to deeply hydrate underlying tissues.13

This mechanism provides immediate relief to dry vaginal cells2. It offers a long-lasting relief while supporting the vaginal lining’s natural repair and maturation processes.

Recognised and Trusted:

Holds M Tick accreditation, enabling menopausal women to easily identify it as the right choice and transition into self-care with confidence.

Make a Lasting Difference

43% of patients discover Replens MD™ Moisturiser through healthcare professionals.*

Your recommendation can transform lives. By starting the conversation about Replens MD™ Moisturiser, you can provide women with a solution that offers lasting benefits.

Just 30 seconds of your time could mean years of comfort for your patients.

*Replens market dynamics understanding - qualitative presentation. Synergy Market Research. 2020 (n=64).

References

NICE. Clinical Knowledge Summaries. Menopause. November 2024. Available at: https://cks.nice.org.uk/topics/menopause/ Last accessed: February 2025.
GPrx Extract Replens claim 2024.
Data on file. CIG Research on Pharmacy Views Attitudes and Opinions. October 2024.
NICE. Menopause: identification and management. NICE guidelines 23. November 2015, updated November 2024. Available at: https://www.nice.org.uk/guidance/ng23 Last accessed: February 2025.
British Menopause Society. What is the menopause? Publication date: October 2021. Review date: October 2024.
Nappi, RE, et al. Vulvar and vaginal atrophy in four European countries: evidence from the European REVIVE survey. Climacteric. 2016;19(2):188–197.
Domoney, C, et al. Symptoms, attitudes and treatment perceptions of vulvo-vaginal atrophy in UK postmenopausal women: results from the REVIVE-EU study. Post Reprod Health. 2020;26(2):101–109.
NHS. About vaginal oestrogen. January 2023. Available at: https://www.nhs.uk/medicines/hormone-replacement-therapy-hrt/vaginal-oestrogen/about-vaginal-oestrogen Last accessed: February 2025.
Bachmann, GA, et al. Vaginal dryness in menopausal women: clinical characteristics and nonhormonal treatment. Clin Pract Sexuality. 1991;7:1–8.
Nachtigall, LE. Comparative study: Replens vs local estrogen in menopausal women. Fertility & Sterility. 1994;61(1):178–180.
British Menopause Society. Consensus statement. Urogenital atrophy. 2023–2024.
Edwards, D, & Panay, N. Treating vulvovaginal atrophy/ genitourinary syndrome of menopause: how important is vaginal lubricant and moisturizer composition? Climacteric. 2016;19(2):151–161.
van der Laak, JAW, et al. The effect of Replens® on vaginal cytology in the treatment of postmenopausal atrophy: cytomorphology versus computerised cytometry. J Clin Pathol. 2002;55:446–451.
Bygdeman, M, & Swahn, ML. Replens versus dienoestrol cream in the symptomatic treatment of vaginal atrophy in postmenopausal women. Maturitas. 1996;23(3):259–263.